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University of Helsinki introduces Neurofeedback
to Finland. Finland is heavily invested in cutting-
edge brain science, yet it has never before had
dealings with neurofeedback (NFB), either in re-
search or clinical practice. However research on
ADHD in Finland has developed strongly (e.g.
Helenius et al., 2011, Gumenyuk et al., 2004)
and thus provides a good ground for the intro-
duction of neurofeedback into Finland.
On par with more global estimates (Polanczyk et
al., 2007), the prevalence of ADHD in Finnish
8-year-olds is estimated at 4% (DSM-III) (Alm-
qvist 2004), while among Finnish 16-18 year
olds it rises to 8.5% (DSM-IV) (Smalley et al.,
2007). Indeed, given that in Finland medication
therapy for ADHD is lowest among all Scandi-
navian countries (Zo ega et al., 2011), Finland’s
need for other treatments may be substantial.
The CENT project will conduct a study on the effects of NFB on
adult ADHD within Finland. Research is being conducted by the
Cognitive Science Unit at the Institute of Behavioural Sciences,
Helsinki University, with NFB conducted by trained technicians
supervised by qualified psychotherapists. Software is custom-built
for the project, with games sourced from local companies.
STUDY DESIGN
The experiment aims to test the efficacy of neurofeedback for
adults with either ADHD or ADD by randomized controlled cli-
nical trial (RCT). The persistence of the treatment effects will also
be tested with a follow-up study. Additionally we will study the
neurological symptoms of adult ADHD/ADD using laboratory-
grade EEG to examine the Event-Related Potentials (ERP) of
patients as they perform attentional tasks, and analyse the pat-
terns of hemispheric activity that characterise them. Both latter
studies will use control groups of healthy non-ADHD/ADD sub-
jects.
Figure 2. shows the study design, with tasks interrelated in time-
line format. From summer 2011 the research, design and prepa-
ration work have been ongoing, ramping up in stages until the
beginning of 2012. Thereafter, the study began in earnest:
Fig.1 EEG-based brain-computer interface
Research phase. Research was conducted into the disorder,
prior NFB studies, and Brain-Computer Interface technology;
using literature review and importantly, fact-finding in centres
of NFB across Europe: Brainclinics in Nijmegen, Netherlands;
Heckscher Klinikum in Mu¨nchen and Niels Birbaumer’s lab at
University of Tu¨bingen, both in Germany.
Design phase. In preparation for the study we obtained Ethical
Approval from the Ethics Committee of Greater Helsinki region;
recruited patients through clinical partners and targeted adverti-
sing campaigns; and screened and conducted intake measurements
of the patients:
- Wechsler’s short-form IQ,
- 128 channel Event-Related Potentials (ERP),
- Test Of Variables of Attention (TOVA) with EEG,
- Vigilance monitoring with EEG.
Piloting phase. NFB training for the assistants who were to
administer the treatment was structured as a validation-test pilot
study where each trainer also acted as a patient, learning the sub-
jective experience of NFB.
Treatment phase Treatment is conducted in the clinics of part-
ner MCC, with patients scheduled to attend on average 3 times
per week. Treatment is ongoing. Every 10 sessions, patients report
on their quality of life and sleep (using Q-LES-Q(SF) - Quali-
ty of Life Enjoyment and Satisfaction Questionnaire and PSQI -
Pittsburgh Sleep Questionnaire). Exhibition of ADHD/ADD re-
lated symptoms and expectations on treatment outcome are also
monitored (through ASRS - Adult ADHD Self-Report Scale and
placebo questionnaire of Borkovec and Sibrava (2005).
Fig.2 Timeline schematic of the Cent study.
HARDWARE
The study is using Neuroelectrics’ Enobio system to feedback pa-
tient’s EEG signals. Enobio is a wireless 4-channel active-electrode
EEG amplifier, which can utilise wet or dry electrodes interchan-
geably. With dry electrodes, uncomfortable abrasive skin prepa-
ration and messy gel is not needed, so recording can start almost
immediately after the subject is ready and electrochemical equili-
brium is established.
Sampling rate: 250Hz
Frequency range: DC-125Hz
Common-Mode Rejection Ratio: 92dB
Signal-to-Noise Ratio: 83dB
Electrodes: active sintered Ag/AgCl
Amplifier noise: 0.5 µV
Driven-Right leg reference
Low-powered radio connection
SOFTWARE
A new software platform was developed by the Finnish company
BLStream for the study, integrating OpenVibe platform’s signal
analysis capabilities with a graphical user interface designed for the
project. The platform gives the researcher or clinician the option
to use different neurofeedback protocols and activities, for example
different games or auditory content. The program records relevant
background information on the patient’s state before each session
and tracks the patient’s progress as the treatment proceeds.
The program is designed for a dual-monitor setup, with separate
monitors for the therapist and the patient. In principle it is pos-
sible for the patient and the therapist to be in different locations
while training, thus enabling tele-neurofeedback.
The training itself is based on thresholds calculated from base-
line measurements. Currently two NFB protocols are supported,
theta-beta (the default option) and SMR; one of these is chosen
by the trainer at the beginning of a session.
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Fig.3 Screenshot of the software used in CENT
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